Quoin Pharmaceuticals Ltd DRC (QNRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.13 (+1.71%), Market cap $0.01B, 52-week low–high $5.17 ~ $22.30.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pha
Financial statements, price targets, institutional (13F) holdings and related news for Quoin Pharmaceuticals Ltd DRC are updated in real time on BlackAll Trade.
Quoin Pharmaceuticals Ltd DRC trades at $7.13 (+1.71%). Real-time quotes and charts are available on BlackAll Trade.
Quoin Pharmaceuticals Ltd DRC has a market cap of about $0.01B.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.